2014
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Annals Of Oncology 2014, 25: 1941-1948. PMID: 25057173, PMCID: PMC4176452, DOI: 10.1093/annonc/mdu269.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSecond-line treatmentProgression-free survivalAdvanced non-small cell lung cancerRandomized phase III studyPhase III studyCell lung cancerMutation-positive tumorsEGFR mutationsIII studyTumor samplesClinical benefitLung cancerSecond-line non-small cell lung cancerEGFR FISH-positive tumorsEGFR mutation-positive tumorsEpidermal growth factor receptor (EGFR) gene mutationsObjective response rateRelative clinical benefitFirst-line chemotherapyObjective tumor responseProtein expressionOverall study populationGene mutationsPretreatment tumor samples
2007
A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
Bepler G, Oh Y, Burris H, Cleverly A, Lahn M, Herbst R. A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2007, 25: 7543-7543. DOI: 10.1200/jco.2007.25.18_suppl.7543.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalThird-line treatmentStable diseaseOverall survivalOral serine/threonine kinase inhibitorMedian progression-free survivalMulticenter phase II trialPrior platinum-based chemotherapyDays of discontinuationMedian overall survivalObjective tumor responsePhase II studyPhase II trialPlatinum-based chemotherapyCell lung cancerWeeks of enrollmentPI3K/Akt pathwayPI3K/AktTumor cell apoptosisOral enzastaurinPFS ratesCommon toxicitiesPrior therapyII study